Effect of medical education on European psychiatrists' knowledge in management of major depressive disorder and psychiatric emergencies

L. Thevathasan, L. Fairley, C. Phillips
2022 European psychiatry  
Introduction The challenge for psychiatrists is keeping up to date with the latest clinical trial data in managing major depressive disorder (MDD) and psychiatric emergencies. Objectives We evaluated whether an online educational video lecture directed at psychiatrists, could improve knowledge and confidence regarding management of psychiatric emergencies associated with MDD. Methods Educational effect was assessed using a 3-question repeated pairs, pre/post assessment survey. A paired-samples
more » ... -test was conducted to assess overall number correct and confidence change. A McNemar's test was conducted to assess question-level significance. P values < 0.05 are statistically significant. Cohen's d test was used to estimate the magnitude of effect of education. The activity launched on 8 April 2021, and preliminary data analysed as of 24 June 2021. Results 807 psychiatrists participated in the programme, of which 150 completed the pre- and post-assessment test. An average overall correct response rate of 44% pre- increased to 74% post- (67% relative increase, P<0.001; Cohen's d = 0.91). Knowledge on the burden of suicide and MDD improved from 38% pre- to 85% post- (124% relative increase,P<0.001). Knowledge regarding clinical data for novel therapies for use in psychiatric emergencies improved from 47% pre- to 68% post- (45% relative increase, P<0.01). Knowledge regarding signs of suicidal intent in patients with MDD improved from 49% pre- to 71% (45% relative increase, P<0.001) following education. Conclusions This study demonstrates the positive effect of online medical education on psychiatrists' knowledge in contemporary management of psychiatric emergencies associated with MDD in Europe. Disclosure The results of this study were from an educational programme that was developed through independent educational funding from Janssen Neuroscience.
doi:10.1192/j.eurpsy.2022.316 fatcat:j64kzlfvijexrkbl65bg6pbt7a